Type I and type II Helicobacter pylori infection status and their impact on gastrin and pepsinogen level in a gastric cancer prevalent area

Table 5 Effects of Helicobacter pylori infection on gastric gastrin 17, pepsinogens levels in stepwise chronic gastric diseases

	NAG	NAGE	PU	CAG	GC
G-17 pmol/L level in different groups,
mean ± SD	5.6 ± 6.2a	6.7 ± 8.3a	9.1 ± 12.2	5.1 ± 6.5a	12.2 ± 7.6
H. pylori (+)	6.9 ± 6.5ac	7.5 ± 8.5ac	9.5 ± 12.6	5.2 ± 6.8a	13.0 ± 7.6c
H. pylori (-)	3.0 ± 4.6	3.9 ± 6.6	5.5 ± 7.4	4.4 ± 5.5	6.0 ± 2.5
Type I H. pylori (+)	7.3 ± 6.7ac	7.6 ± 8.4ac	10.9 ± 13.8e	25.3 ± 7.4a	13.8 ± 7.9c
Type II H. pylori (+)	6.0 ± 6.2c	7.3 ± 9.0	4.6 ± 4.9	4.8 ± 3.2	8.9 ± 4.5
PG I µg/L level in different groups,
mean ± SD	116.5 ± 72.4ag	116.0 ± 74.2ag	168.7 ± 103.7	103.1 ± 60.2ag	168.6 ± 103.5
H. pylori (+)	117.0 ± 69.8g	117.5 ± 74.8g	172.9 ± 105.0	101.4 ± 64.4ag	169.4 ± 104.9
H. pylori (-)	115.4 ± 77.6	110.7 ± 73.6	128.8 ± 86.2	110.3 ± 64.3	162.0 ± 103.7
Type I H. pylori (+)	118.4 ± 67.5ag	113.9 ± 62.6ag	178.1 ± 109.6	100.6 ± 65.0ag	170.8 ± 96.3
Type II H. pylori (+)	114.0 ± 75.1	123.4 ± 92.9	154.9 ± 87.2	105.9 ± 78.6	162.1 ± 154.5
PG II µg/L level in different groups,
mean ± SD	13.7 ± 11.2ag	14.4 ± 12.1a	19.5 ± 14.3	13.8 ± 10.1ag	24.5 ± 15.9
H. pylori (+)	15.3 ± 11.3ac	15.9 ± 13.0ac	20.4 ± 14.7c	14.8 ± 11.0ac	25.1 ± 15.9
H. pylori (-)	10.5 ± 10.2	8.9 ± 5.5	10.8 ± 4.8	8.7 ± 4.3	20.6 ± 16.5
Type I H. pylori (+)	17.1 ± 12.0ce	16.5 ± 11.3c	21.9 ± 16.0ce	14.7 ± 11.3ac	25.5 ± 16.3
Type II H. pylori (+)	11.5 ± 8.6	14.9 ± 15.5	15.1 ± 6.8	15.4 ± 9.6c	22.8 ± 15.3
PG I/PG II ratios in different groups,
mean ± SD	10.6 ± 6.3ai	9.6 ± 5.4a	9.7 ± 4.3a	7.9 ± 4.4a	5.6 ± 3.8
H. pylori (+)	9.3 ± 5.6aci	8.7 ± 4.6ac	9.5 ± 4.4ai	6.8 ± 3.3c	5.1 ± 3.0
H. pylori (-)	13.2 ± 7.0	13.1 ± 6.7	11.8 ± 3.7	12.8 ± 4.7	9.1 ± 7.3
Type I H. pylori (+)	8.2 ± 4.9ace	7.8 ± 3.3ace	9.2 ± 4.2a	6.5 ± 3.2c	4.7 ± 2.9c
Type II H. pylori (+)	11.4 ± 6.3	10.3 ± 5.9	10.7 ± 4.9	8.8 ± 3.4c	7.6 ± 2.1

^aP < 0.05, vs gastric cancer patients;

^cP < 0.05, vs H. pylori-negative patients in the same disease groups;

^eP < 0.05, type I and type II H. pylori-positive patients were compared in the same disease groups;

^gP < 0.05, vs peptic ulcer patients;

ⁱP < 0.05, vs chronic atrophic gastritis patients. CAG: Chronic atrophic gastritis; G-17: Gastrin 17; GC: Gastric cancer; H. pylori: Helicobacter pylori; NAG: Non-atrophic gastritis; NAGE: Non-atrophic gastritis with erosion; PU: Peptic ulcer; PG I: Pepsinogen I; PG II: Pepsinogen II; PG I/PG II: Pepsinogen I /pepsinogen II ratio.